The efficacy and safety of up to 24 weeks of triptorelin therapy
following conservative surgery in patients with deep infiltrating
endometriosis (DIE): a multicentre, prospective, non-interventional
study in China
Abstract
OBJECTIVE: To evaluate the efficacy and safety of up to 24 weeks of
triptorelin treatment after conservative surgery for deep infiltrating
endometriosis (DIE). DESIGN: Multicentre, prospective,
non-interventional. SETTING: 18 tertiary hospitals in China. POPULATION:
Premenopausal women aged ≥ 18 years treated with triptorelin 3.75 mg
once every 28 days for up to 24 weeks after conservative surgery for DIE
METHODS: Endometriosis symptoms were assessed, using a visual analogue
scale (0–10 cm) or numerical range (0–10), at baseline (pre-surgery)
and routine visits 3, 6, 9, 12, 18 and 24 months after surgery. MAIN
OUTCOME MEASURES: Change in symptom intensity over time. RESULTS: A
total of 384 women were analysed (mean [SD] age, 33.4 [6.2]
years). Scores for all symptoms assessed (pelvic pain, dysmenorrhoea,
ovulation pain, dyspareunia, menorrhagia, metrorrhagia and
gastrointestinal and urinary symptoms) decreased from baseline over 24
months. Cumulative improvement rates in pelvic pain, dysmenorrhoea,
ovulation pain and dyspareunia were 74.4%, 83.6%, 55.1% and 66.9%,
respectively. The 24-month cumulative recurrence rate (≥ 1 symptom) was
22.2%. The risk of symptom recurrence was higher in patients with ≥ 2
versus 1 lesion (odds ratio [OR] 2.539; 95% CI: 1.458–4.423; p =
0.001) and patients with moderate (OR 5.733; 95% CI: 1.623–20.248; p =
0.007) or severe (OR 8.259; 95% CI: 2.449–27.851; p = 0.001) pain
versus none/mild pain. Triptorelin was well tolerated. CONCLUSIONS:
Triptorelin after conservative surgery for DIE improved symptoms over 24
months of follow up. FUNDING: Sponsored by Ipsen